Akiram Therapeutics is set to present the first clinical results for its investigational candidate AKIR001 at the EANM 2026 congress, according to FirstWord Pharma.
The company announced the upcoming presentation on Tuesday, October 13, 2026, per the report. The EANM congress is the annual meeting of the European Association of Nuclear Medicine, a setting where nuclear medicine and molecular imaging research is typically shared.
FirstWord Pharma's report did not include the full details of the presentation, and no data from the trial were disclosed in the material available. The specific findings, study design, and patient population for AKIR001 have not yet been made public.
The disclosure marks the first time clinical results for AKIR001 will be shared publicly, based on the headline and summary from FirstWord Pharma. Further specifics on the format of the presentation and the session in which it will appear were not provided in the reporting.
What to watch next: the actual AKIR001 clinical data once Akiram Therapeutics presents them at EANM 2026, along with any additional details the company releases around the congress.
